Evergreen Youth Secrets
  • Health News
  • Health Care
  • Staying Healthy
  • Beauty Advices
  • Health News
  • Health Care
  • Staying Healthy
  • Beauty Advices
No Result
View All Result
Evergreen Youth Secrets
No Result
View All Result
Home Health Care

FDA recalls thousands of antidepressant bottles due to cancer-causing chemical

by
October 23, 2024
in Health Care
0
FDA recalls thousands of antidepressant bottles due to cancer-causing chemical

The Food and Drug Administration (FDA) issued a Class II recall of more than 7,100 bottles of the antidepressant duloxetine due to the possible presence of a carcinogen.  

Duloxetine belongs to a group of drugs called selective serotonin and norepinephrine reuptake inhibitors that are used to treat depression and anxiety, according to the Mayo Clinic.  

A recall of the common antidepressant drug, also sold under the brand name Cymbalta, was first issued by the agency on Oct. 10. 

The FDA noted that the drug had the “presence” of nitrosamine drug substance-related impurity above the acceptable intake limit.  

Now, the FDA has downgraded the risk level associated with the drug recall to a Class II, which is issued when the use or exposure of a product “may cause temporary or medically reversible adverse health outcomes.” 

Class II recalls are also issued when the likelihood of severe health outcomes from exposure or use of a product is “remote,” according to the agency’s website. 

Nitrosamine impurities can increase the risk of cancer if “people are exposed to them above acceptable levels and over long periods of time,” according to the FDA.  

The agency is specifically recalling 7,107 bottles of duloxetine delayed-release capsules manufactured by Towa Pharmaceutical Europe. The capsules are 20 milligram doses and come in bottles of 500 pills.  

Neither Towa Pharmaceutical Europe nor its American subsidiary Breckenridge Pharmaceutical Inc have responded to requests for comment from The Hill.  

Towa is working with the FDA and other regulators to implement the recall, the company wrote in an email to The Hill.

“As always, patient safety remains our top priority,” the company said.

At this time, Towa Pharmaceutical Europe is working with the FDA and other regulators to implement the recall.

People taking a prescription medication with potential nitrosamine impurities should stop taking the drug and speak with their health care provider about their concerns and other treatment options, per the FDA website.  

Previous Post

Democrats urge appeals court to uphold hospitals’ emergency abortion care

Next Post

Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats

Next Post
Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats

Novo Nordisk asks FDA to block compounding pharmacies from making Ozempic copycats

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

    Popular News

    New Hampshire lawmakers give final approval to gender-affirming care ban 

    New Hampshire lawmakers give final approval to gender-affirming care ban 

    June 27, 2025
    FDA expanding COVID vaccine warnings over rare heart side effect

    FDA expanding COVID vaccine warnings over rare heart side effect

    June 27, 2025
    Supreme Court upholds HHS authority over ObamaCare preventative care task force

    Supreme Court upholds HHS authority over ObamaCare preventative care task force

    June 27, 2025

    Trending

    2 House Republicans seek to stop IVF expansion in defense bill

    2 House Republicans seek to stop IVF expansion in defense bill

    November 21, 2024
    Trump gives GOP moderates ‘very helpful’ breathing room on abortion

    Trump gives GOP moderates ‘very helpful’ breathing room on abortion

    June 18, 2024
    Fauci says he still fears someone may kill him

    Fauci says he still fears someone may kill him

    June 19, 2024
    RFK Jr. issues rule barring public comment on HHS rulemaking

    RFK Jr. issues rule barring public comment on HHS rulemaking

    February 28, 2025

    Recent News

    New Hampshire lawmakers give final approval to gender-affirming care ban 

    New Hampshire lawmakers give final approval to gender-affirming care ban 

    June 27, 2025
    FDA expanding COVID vaccine warnings over rare heart side effect

    FDA expanding COVID vaccine warnings over rare heart side effect

    June 27, 2025

    Popular News

    • New Hampshire lawmakers give final approval to gender-affirming care ban 
    • FDA expanding COVID vaccine warnings over rare heart side effect

    About Evergreen Youth Secrets

    • Contact us
    • Privacy Policy
    • Terms & Conditions
    • Email Whitelisting

    Copyright © 2025 Evergreenyouthsecrets.com. All Rights Reserved.

    No Result
    View All Result
    • Health News
    • Health Care
    • Staying Healthy
    • Beauty Advices

    Copyright © 2025 Evergreenyouthsecrets.com. All Rights Reserved.